ErbB2 dephosphorylation and anti-proliferative effects of neuregulin-1 in erbb2-overexpressing cells; Re-evaluation of their low-affinity interaction

Scientific Reports

Volumn 3, Issue , 2013, Pages

  Wang, Ran ^a,b   Iwakura, Yuriko ^a   Araki, Kazuaki ^a   Keino Masu, Kazuko ^c   Masu, Masayuki ^c   Wang, Xue Yi ^b   Takei, Nobuyuki ^a   Higashiyama, Shigeki ^d   Nawa, Hiroyuki ^a  

^a NIIGATA UNIVERSITY   (Japan)

^b HEBEI MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF TSUKUBA   (Japan)

^d EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; NEU DIFFERENTIATION FACTOR;

ARTICLE; BINDING COMPETITION; CELL LINE; CELL PROLIFERATION; DRUG EFFECT; GENE EXPRESSION; GENETICS; HUMAN; METABOLISM; PHOSPHORYLATION; PROTEIN BINDING;

BINDING, COMPETITIVE; CELL LINE; CELL PROLIFERATION; GENE EXPRESSION; HUMANS; NEUREGULIN-1; PHOSPHORYLATION; PROTEIN BINDING; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3;

EID: 84875186429     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep01402     Document Type: Article

References (49)

1. Peles, E. et al. Isolation of the neu/HER-2 stimulatory ligand: a 44 kd glycoprotein that induces differentiation of mammary tumor cells. Cell 69, 205-216 (1992).
2. Holmes, W. E. et al. Identification of heregulin, a specific activator of p185erbB2. Science 256, 1205-1210 (1992).
3. Peles, E. et al. Cell-type specific interaction of Neu differentiation factor (NDF/heregulin) with Neu/HER-2 suggests complex ligand-receptor relationships. EMBO J 12, 961-971 (1993). (Pubitemid 23095845)
4. Sliwkowski, M. X. et al. Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. J Biol Chem 269, 14661-14465 (1994).
5. Karunagaran, D. et al. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J 15, 254-264 (1996). (Pubitemid 26029205)
6. Graus-Porta, D., Beerli, R. R., Daly, J. M. & Hynes, N. E. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is amediator of lateral signaling. EMBO J 16, 1647-1655 (1997). (Pubitemid 27151960)
7. Neve, R. M. et al. Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells. Oncogene 19, 1647-1656 (2000). (Pubitemid 30200966)
8. Clinchy, B. et al. The growth and metastasis of human, HER-2/neuoverexpressing tumor cell lines in male SCID mice. Breast Cancer Res Treat 61, 217-228 (2000). (Pubitemid 30609555)
9. Olayioye, M. A. Update on HER-2 as a target for cancer therapy: intracellular signaling pathways of ErbB2/HER-2 and family members. Breast Cancer Res 3, 385-389 (2001). (Pubitemid 34196365)
10. Penuel, E., Akita, R. W. & Sliwkowski, M. X. Identification of a region within the ErbB2/HER2 intracellular domain that is necessary for ligand-independent association. J Biol Chem 277, 28468-28473 (2002). (Pubitemid 41079271)
11. Slamon, D. J. et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177-182 (1987). (Pubitemid 17231334)
12. Ursini-Siegel, J., Schade, B., Cardiff, R. D. & Muller, W. J. Insights from transgenic mouse models of ERBB2-induced breast cancer. Nature Reviews Cancer 7, 389-397 (2007). (Pubitemid 46652484)
13. Drebin, J. A., Link, V. C., Stern, D. F., Weinberg, R. A. & Greene, M. I. Downmodulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell 41, 697-706 (1985).
14. Nagy, P. et al. Lipid rafts and the local density of ErbB proteins influence the biological role of homo-and heteroassociations of ErbB2. J Cell Sci 115, 4251-4262 (2002). (Pubitemid 35460696)
15. Santin, A. D., Bellone, S., Roman, J. J., McKenney, J. K.&Pecorelli, S. Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu. Int J Gynaecol Obstet 102, 128-131 (2008).
16. Roy, V. & Perez, E. A. Beyond trastuzumab: small molecule tyrosine kinase inhibitors in HER-2-positive breast cancer. Oncologist 14, 1061-1069 (2009).
17. Tan, M. & Yu, D. Molecular mechanisms of erbB2-mediated breast cancer chemoresistance. Adv Exp Med Biol 608, 119-129 (2007).
18. Fitzpatrick, V. D., Pisacane, P. I., Vandlen, R. L. & Sliwkowski, M. X. Formation of a high affinity heregulin binding site using the soluble extracellular domains of ErbB2 with ErbB3 or ErbB4. FEBS Lett 431, 102-106 (1998). (Pubitemid 28330861)
19. Tzahar, E. et al. Bivalence of EGF-like ligands drives the ErbB signaling network. EMBO J 16, 4938-4950 (1997). (Pubitemid 27348403)
20. Pankonin, M. S., Gallagher, J. T. & Loeb, J. A. Specific structural features of heparan sulfate proteoglycans potentiate neuregulin-1 signaling. J Biol Chem 280, 383-388 (2005). (Pubitemid 40165002)
21. Lafky, J. M.,Wilken, J. A., Baron, A. T. &Maihle, N. J. Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. Biochim Biophys Acta 1785, 232-265 (2008).
22. Khurana, A., Beleford, D., He, X., Chien, J. & Shridhar, V. Role of heparan sulfatases in ovarian and breast cancer. Am J Cancer Res 3, 34-45 (2013).
23. Kihara, A. & Pastan, I. Cytotoxic activity of chimeric toxins containing the epidermal growth factor-like domain of heregulins fused to PE38KDEL, a truncated recombinant form of Pseudomonas exotoxin. Cancer Res 55, 71-77 (1995).
24. Schneider, B. et al. Potent antitumoral activity of TRAIL through generation of tumor-targeted single-chain fusion proteins. Cell Death Dis 1, e68 (2010).
25. Iwakura, Y. et al. Qualitative and quantitative re-evaluation of epidermal growth factor-ErbB1 action on developing midbrain dopaminergic neurons in vivo and in vitro: target-derived neurotrophic signaling (Part 1). J Neurochem 118, 45-56 (2011).
26. Shibuya, M. et al. Measurement and comparison of serum neuregulin 1 immunoreactivity in control subjects and patients with schizophrenia: an influence of its genetic polymorphism. J Neural Transm 117, 887-895 (2010).
27. Nagamine, S. et al. Organ-specific sulfation patterns of heparan sulfate generated by extracellular sulfatases Sulf1 and Sulf2 in mice. J Biol Chem 287, 9579-9590 (2012).
28. Wang, R. et al. In vitro production of an active neurotrophic factor, neuregulin-1: qualitative comparison of different cell-free translation systems. Neurosci Lett 497, 90-93 (2011).
29. Chan, R., Hardy, W. R., Dankort, D., Laing, M. A. & Muller, W. J. Modulation of Erbb2 signaling during development: a threshold level of Erbb2 signaling is required for development. Development 131, 5551-5560 (2004). (Pubitemid 39625199)
30. Brockhoff, G., Heiss, P., Schlegel, J., Hofstaedter, F. & Knuechel, R. Epidermal growth factor receptor, c-erbB2 and c-erbB3 receptor interaction, and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma cells. Cytometry 44, 338-348 (2001).
31. Lodish, H. F.&Kong, N. The secretory pathway is normal in dithiothreitol-treated cells, but disulfide-bonded proteins are reduced and reversibly retained in the endoplasmic reticulum. J Biol Chem 268, 20598-20605 (1993). (Pubitemid 23278975)
32. Sartor, C. I. et al. Her4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cells. Mol Cell Biol 21, 4265-4275 (2001). (Pubitemid 32565308)
33. Muraoka-Cook, R. S. et al. Heregulin-dependent delay in mitotic progression requires HER4 and BRCA1. Mol Cell Biol 26, 6412-6424 (2006). (Pubitemid 44277882)
34. Daly, J. M. et al. Neu differentiation factor induces ErbB2 down-regulation and apoptosis of ErbB2-overexpressing breast tumor cells. Cancer Res 57, 3804-3811 (1997). (Pubitemid 27381227)
35. Ouyang, X.,Gulliford, T.&Epstein, R. J. The duration of phorbol-inducible ErbB2 tyrosine dephosphorylation parallels that of receptor endocytosis rather than threonine-686 phosphorylation: implications for the physiological role of protein kinase C in growth factor receptor signaling. Carcinogenesis 19, 2013-2019 (1998). (Pubitemid 28521946)
36. Segatto, O., Anastasi, S. & Alemà, S. Regulation of epidermal growth factor receptor signaling by inducible feedback inhibitors. J Cell Sci 124, 1785-1793 (2011).
37. Jaulin-Bastard, F. et al. Interaction between Erbin and a Catenin-related protein in epithelial cells. J Biol Chem 277, 2869-2875 (2002). (Pubitemid 34953320)
38. Tao, Y. et al. Erbin regulates NRG1 signaling and myelination. Proc Natl Acad Sci USA 106, 9477-9482 (2009).
39. Hasleka?s, C. et al. The inhibitory effect of ErbB2 on epidermal growth factorinduced formation of clathrin-coated pits correlates with retention of epidermal growth factor receptor-ErbB2 oligomeric complexes at the plasma membrane. Mol Biol Cell 16, 5832-5842 (2005). (Pubitemid 41752230)
40. Fiorentino, L. et al. Inhibition of ErbB-2 mitogenic and transforming activity by RALT, a mitogen-induced signal transducer which binds to the ErbB-2 kinase domain. Mol Cell Biol 20, 7735-7750 (2000).
41. Anastasi, S. et al. Feedback inhibition by RALT controls signal output by the ErbB network. Oncogene 22, 4221-4234 (2003). (Pubitemid 36876243)
42. Frosi, Y. et al. A two-tiered mechanism of EGFR inhibition by RALT/MIG6 via kinase suppression and receptor degradation. J Cell Biol 189, 557-571 (2010).
43. Santra, M., Eichstetter, I.&Iozzo, R. V. An anti-oncogenic role for decorin. Downregulation of ErbB2 leads to growth suppression and cytodifferentiation of mammary carcinoma cells. J Biol Chem 275, 35153-35161 (2000).
44. Nakano, N. et al. The N-terminal region of NTAK/neuregulin-2 isoforms has an inhibitory activity on angiogenesis. J Biol Chem 279, 11465-11470 (2004). (Pubitemid 38401646)
45. Falcioni, R. et al. Alpha 6 beta 4 and alpha 6 beta 1 integrins associate with ErbB-2 in human carcinoma cell lines. Exp Cell Res 236, 76-85 (1997). (Pubitemid 27452351)
46. Ieguchi, K. et al. Direct binding of the EGF-like domain of neuregulin-1 to integrins ({alpha}v{beta}3 and {alpha}6{beta}4) is involved in neuregulin-1/ErbB signaling. J Biol Chem 285, 31388-31398 (2010).
47. Tanizaki, J., Okamoto, I., Sakai, K. & Nakagawa, K. Differential roles of transphosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification. Br J Cancer 105, 807-813 (2011).
48. Yamamoto, T. et al. Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature 319, 230-234 (1986). (Pubitemid 16128786)
49. Kinugasa, Y. et al. Neuroglycan C, a novel member of the neuregulin family. Biochem Biophys Res Commun 321, 1045-1049 (2004). (Pubitemid 39044415)